This particular AD-model triple-transgenic model (3 × Tg-AD) harbours the PS1M146V (a presenilin 1 mutant), APPSwe (a β-amyloid precursor protein mutant), and tauP301L (a p-tau mutant) transgenes and was specifically developed for evaluating the impact potential AD therapeutics of both amyloid plaque and p-tau tangle pathology on synaptic function [42]. This evidence concerns the gene MAPT and Alzheimer disease.